Details

Autor(en) / Beteiligte

• Habermann, Felix-Nikolai Oschinka Jegor
• Schmitt, Daniela
• Failing, Thomas
• Ziegler, David Alexander
• Fischer, Jann
• Fischer, Laura Anna
• Guhlich, Manuel
• Bendrich, Stephanie
• Knaus, Olga
• Overbeck, Tobias Raphael
• Treiber, Hannes
• von Hammerstein-Equord, Alexander
• Koch, Raphael
• El Shafie, Rami
• Rieken, Stefan
• Leu, Martin
• Dröge, Leif Hendrik

Titel

And Yet It Moves: Clinical Outcomes and Motion Management in Stereotactic Body Radiation Therapy (SBRT) of Centrally Located Non-Small Cell Lung Cancer (NSCLC): Shedding Light on the Internal Organ at Risk Volume (IRV) Concept

Ist Teil von

• Cancers, 2024-01, Vol.16 (1), p.231

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2024

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• The internal organ at risk volume (IRV) concept might improve toxicity profiles in stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). We studied (1) clinical aspects in central vs. peripheral tumors, (2) the IRV concept in central tumors, (3) organ motion, and (4) associated normal tissue complication probabilities (NTCPs). We analyzed patients who received SBRT for NSCLC (clinical aspects, = 78; motion management, = 35). We found lower biologically effective doses, larger planning target volume sizes, higher lung doses, and worse locoregional control for central vs. peripheral tumors. Organ motion was greater in males and tall patients (bronchial tree), whereas volume changes were lower in patients with a high body mass index (BMI) (esophagus). Applying the IRV concept (retrospectively, without new optimization), we found an absolute increase of >10% in NTCPs for the bronchial tree in three patients. This study emphasizes the need to optimize methods to balance dose escalation with toxicities in central tumors. There is evidence that organ motion/volume changes could be more pronounced in males and tall patients, and less pronounced in patients with higher BMI. Since recent studies have made efforts to further subclassify central tumors to refine treatment, the IRV concept should be considered for optimal risk assessment.